For patients with stage IV NSCLC and driver alterations, the ASCO Living Guidelines (version 2022.3) recommend standalone osimertinib for patients with EGFR mutation (L858R/exon 19 deletions, with or without concomitant T790M) with PS of 0–2. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.